Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Viking Therapeutics, Inc. (VKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 3.62 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2024-02-07
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2021-12-31 was -1.11M shares, a 949.39% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2021-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2021-06-30 was 922.09K shares, a 542.37% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2021-03-31 was 2.70M shares, a 38144.33% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2022 was 3.62M shares, a 0.00% change from fiscal 2021.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2021 was 3.62M shares, a 938.27% increase from fiscal 2020.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2020 was 348.49K shares, a 34.08% decline from fiscal 2019.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2019 was 528.70K shares, a 85.51% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month |
|---|---|---|---|---|
| 2022-12-31 | 3.62M shares 10-K · filed 2023-02-10 | |||
| 2021-12-31 | -1.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | -1.11M shares derived: sum of 2 quarters · filed 2024-02-07 | -187.91K shares derived: sum of 3 quarters · filed 2024-02-07 | 3.62M shares 10-K · filed 2024-02-07 |
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-03 | 922.09K shares derived: sum of 2 quarters · filed 2021-11-03 | 4.73M shares 10-Q · filed 2021-11-03 | 3.75M shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-06-30 | 922.09K shares 10-Q · filed 2021-07-28 | 3.62M shares 10-Q · filed 2021-07-28 | 3.75M shares derived: sum of 3 quarters · filed 2022-02-09 | 3.82M shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-03-31 | 2.70M shares 10-Q · filed 2021-04-28 | 2.83M shares derived: sum of 2 quarters · filed 2022-02-09 | 2.89M shares derived: sum of 3 quarters · filed 2022-02-09 | 3.04M shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | 130.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | 197.90K shares derived: sum of 2 quarters · filed 2022-02-09 | 341.44K shares derived: sum of 3 quarters · filed 2022-02-09 | 348.49K shares 10-K · filed 2022-02-09 |
| 2020-09-30 | 67.22K shares 10-Q · filed 2020-10-28 | 210.76K shares derived: sum of 2 quarters · filed 2020-10-28 | 217.81K shares 10-Q · filed 2020-10-28 | 355.95K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-06-30 | 143.54K shares 10-Q · filed 2020-07-29 | 150.59K shares 10-Q · filed 2020-07-29 | 288.74K shares derived: sum of 3 quarters · filed 2021-02-17 | 322.93K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-03-31 | 7.05K shares 10-Q · filed 2020-04-30 | 145.19K shares derived: sum of 2 quarters · filed 2021-02-17 | 179.38K shares derived: sum of 3 quarters · filed 2021-02-17 | 295.99K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-12-31 | 138.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | 172.33K shares derived: sum of 2 quarters · filed 2021-02-17 | 288.94K shares derived: sum of 3 quarters · filed 2021-02-17 | 528.70K shares 10-K · filed 2021-02-17 |
| 2019-09-30 | 34.19K shares 10-Q · filed 2019-11-05 | 150.79K shares derived: sum of 2 quarters · filed 2019-11-05 | 390.56K shares 10-Q · filed 2019-11-05 | 765.34K shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2019-06-30 | 116.60K shares 10-Q · filed 2019-08-01 | 356.36K shares 10-Q · filed 2019-08-01 | 731.15K shares derived: sum of 3 quarters · filed 2020-02-26 | 1.63M shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2019-03-31 | 239.76K shares 10-Q · filed 2019-05-02 | 614.54K shares derived: sum of 2 quarters · filed 2020-02-26 | 1.52M shares derived: sum of 3 quarters · filed 2020-02-26 | 2.41M shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-12-31 | 374.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | 1.28M shares derived: sum of 2 quarters · filed 2020-02-26 | 2.17M shares derived: sum of 3 quarters · filed 2020-02-26 | 3.65M shares 10-K · filed 2020-02-26 |
| 2018-09-30 | 902.91K shares 10-Q · filed 2018-11-07 | 1.79M shares derived: sum of 2 quarters · filed 2018-11-07 | 3.27M shares 10-Q · filed 2018-11-07 | |
| 2018-06-30 | 889.15K shares 10-Q · filed 2018-08-09 | 2.37M shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 1.48M shares 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | 452.30K shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |